<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408499</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000517090</org_study_id>
    <secondary_id>P30CA093373</secondary_id>
    <secondary_id>UCDCC-177</secondary_id>
    <secondary_id>BMS-4608</secondary_id>
    <secondary_id>BMS-CA225-261</secondary_id>
    <nct_id>NCT00408499</nct_id>
  </id_info>
  <brief_title>Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
      cells and help kill them or carry tumor-killing substances to them. Giving erlotinib together
      with cetuximab may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib and
      cetuximab and to see how well they work in treating patients with advanced solid tumors or
      progressive or recurrent stage III or stage IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the safety and feasibility of erlotinib hydrochloride and cetuximab in
           patients with advanced solid tumors. (Phase I)

        -  Determine the efficacy of this regimen, in terms of objective tumor response rate, in
           patients with advanced non-small cell lung cancer (NSCLC) pre-treated with platinum.
           (Phase II)

      Secondary

        -  Determine the maximum tolerated dose of this regimen in these patients. (Phase I)

        -  Determine the efficacy of this regimen, in terms of response rate, in these patients.
           (Phase I)

        -  Determine the progression-free and overall survival of patients treated with this
           regimen. (Phase II)

        -  Determine the frequency and severity of toxicities of this regimen in these patients.
           (Phase II)

        -  Determine epidermal growth factor receptor (EGFR) and K-RAS mutation status. (Phase II)

        -  Evaluate EGFR protein expression and protein expression of downstream markers (e.g.,
           pMAPK, pAKT, p27, and Ki-67). (Phase II)

        -  Evaluate the levels of marker proteins (e.g., pMAPK, pAKT, p27, and Ki-67) in buccal
           cells. (Phase II)

        -  Determine gene copy number by EGFR fluorescent in situ hybridization (FISH). (Phase II)

        -  Identify EGFR polymorphisms by analysis of genomic DNA from peripheral blood mononuclear
           cells. (Phase II)

        -  Determine if the continued presence or absence of mutant K-RAS tumor DNA correlates with
           response and/or outcome. (Phase II)

      OUTLINE: This is a phase I, dose-escalation study followed by an open-label, phase II study.

        -  Phase I: Patients receive oral erlotinib hydrochloride once daily on days 1-28 and
           cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days in
           the absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of erlotinib hydrochloride and cetuximab
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose
      preceding that at which â‰¥ 2 of 6 patients experience dose-limiting toxicity. At least 6
      patients are treated at the MTD.

        -  Phase II: Patients receive erlotinib hydrochloride and cetuximab at the MTD determined
           in phase I.

      Blood and buccal samples are acquired from patients at baseline and prior to courses 2 and 3.
      Samples are examined by fluorescent in situ hybridization (FISH), immunohistochemistry,
      polymorphism analysis, and protein expression assays to assess molecular markers (epidermal
      growth factor receptor, K-RAS, pMAPK, pAKT, p27 and Ki-67) for biologic effects and
      predictive response.

      After completion of phase I treatment, patients are followed for 30 days or until all
      toxicities resolve. After completion of phase II treatment, patients are followed
      periodically.

      PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Experiencing a DLT</measure>
    <time_frame>baseline through cycle 1 of treatment</time_frame>
    <description>Patients will be followed during cycle 1 for the occurrence of a protocol defined dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Correlated With Best Overall Response.</measure>
    <time_frame>Every two cycles from first dose to last dose of study drugs</time_frame>
    <description>To determine the efficacy, as measured by objective tumor response rate (RICIST criteria), of daily oral erlotinib and weekly intravenous cetuximab in patients with advanced NSCLC. Best overall response per patient will be reported below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Outcome</measure>
    <time_frame>Patients will be followed until death</time_frame>
    <description>In the Phase II portion of the study, patients will be followed for both disease free progression by capturing disease progression date and for over all survival by capturing death date.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Erlotinib + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily erlotinib combined with weekly cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.</description>
    <arm_group_label>Erlotinib + Cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.</description>
    <arm_group_label>Erlotinib + Cetuximab</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  For the phase I portion of the study (completed 10/05/08), patients must have
             cytologically or histologically proven advanced solid tumors for which there is no
             standard effective therapy available.

          -  Any number of prior chemotherapy regimens are allowed for the both the Phase I and
             Phase II portions

          -  For the phase II portion patients must have cytologically or histologically proven
             selected stage IIIB (pleural effusion) or IV NSCLC. Patients with NSCLC that have
             progressed or recurred after first-line therapy for stage IIIA or IIIB may also be
             considered.

          -  Patients must have measurable disease by RECIST criteria for the Phase II portion.
             Disease in previously irradiated sites is considered measurable if there is clear
             disease progression following radiation therapy. Patients with evaluable disease (bone
             metastases, pleural fluid, ascites, etc.) may be included in the phase I portion of
             the trial (completed 10/08/08).

          -  Must be 18 years of age or older.

          -  Patients must have a performance status of 0 -2.

          -  Patients must have an estimated survival of at least 3 months.

          -  Any prior chemotherapy must have been completed at least 4 weeks prior to start of
             treatment. For prior mitomycin chemotherapy a 6-week interval is required. Prior
             radiation must have been completed at least 2 weeks prior to start of therapy.
             Patients must have recovered from acute reversible medically significant side effects
             of prior chemotherapy regimens or radiotherapy to NCI-CTC &lt; grade 1 (excluding
             alopecia). Prior herceptin is allowed.

          -  Patients must have adequate renal function as documented by a serum creatinine &lt; 1.5
             mg/dl or a calculated creatinine clearance of &gt; 45 ml/min (see protocol Appendix D for
             formula for calculating creatinine clearance).

          -  Patients must have adequate liver function as documented by serum bilirubin &lt; 1.5 x
             ULN. AST must be &lt; 2.5 x institutional upper limit of normal.

          -  Patients must have a pretreatment granulocyte count of &gt;1500/mm3 and platelet count of
             &gt;100 000/mm3.

          -  Patients with asymptomatic treated brain metastasis (surgical resection or
             radiotherapy) may be included if they are neurologically stable and have been off
             steroids and anticonvulsants for at least 2 weeks.

          -  All patients must give voluntary written informed consent.

          -  Patients must be able to take and retain oral medication.

          -  Documentation of a negative serum pregnancy test.

          -  Patients on coumadin should have their INR monitored at least once per week or more
             frequently depending on the investigator's judgment. There have been some case reports
             of increased INR when coumadin is co-administered with erlotinib.

        Exclusion criteria

          -  Patients who have received erlotinib, cetuximab, or any other EGFR-directed therapy
             (excluding herceptin).

          -  Patients with symptomatic brain metastasis or still requiring steroids and
             anti-convulsants may not be included.

          -  For the phase II portion of the study, no other prior malignancy is allowed except for
             the following: adequately treated basal cell or squamous cell skin cancer, in situ
             cervical cancer, adequately treated stage I or II cancer from which the patient is
             currently in complete remission, and any other cancer from which the patient has been
             disease-free for over five years

          -  Patients with acute hepatitis or known HIV.

          -  Patients with active or uncontrolled infection.

          -  Patients with significant history of uncontrolled cardiac disease; i.e., uncontrolled
             hypertension, unstable angina, recent myocardial infarction (within prior 6 months),
             uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection
             fraction.

          -  Patients with prior severe infusion reaction to a monoclonal antibody.

          -  Any concurrent chemotherapy not indicated in the study protocol or any other
             investigational agent(s).

          -  Pregnant or breastfeeding females as the effects of these drugs on the unborn fetus
             are unknown.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Gandara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2006</study_first_posted>
  <results_first_submitted>January 19, 2017</results_first_submitted>
  <results_first_submitted_qc>March 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2017</results_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1</title>
          <description>100 mg Erlotinib, 150 mg/m2 Cetuximab</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2</title>
          <description>100 mg Erlotinib, 200 mg/m2 Cetuximab</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3</title>
          <description>100 mg Erlotinib, 250 mg/m2 Cetuximab</description>
        </group>
        <group group_id="P4">
          <title>Dose Level 4</title>
          <description>150 mg Erlotinib, 250 mg/m2 Cetuximab</description>
        </group>
        <group group_id="P5">
          <title>Phase II- Dose Expansion</title>
          <description>Phase II dose expansion at determined MTD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1: Dose Levels 1-4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II- MTD Expansion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>treatment delay</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib + Cetuximab</title>
          <description>cetuximab: Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
erlotinib: Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.91" lower_limit="38" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Experiencing a DLT</title>
        <description>Patients will be followed during cycle 1 for the occurrence of a protocol defined dose limiting toxicity</description>
        <time_frame>baseline through cycle 1 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>100 mg Erlotinib, 150 mg/m2 Cetuximab</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>100 mg Erlotinib, 200 mg/m2 Cetuximab</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3</title>
            <description>100 mg Erlotinib, 250 mg/m2 Cetuximab</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 4</title>
            <description>150 mg Erlotinib, 250 mg/m2 Cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing a DLT</title>
          <description>Patients will be followed during cycle 1 for the occurrence of a protocol defined dose limiting toxicity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Maximum tolerated dose was derived from toxicity data obtained from dose level 1-4.</non_inferiority_desc>
            <param_type>Maximum tolerated dose</param_type>
            <param_value>4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Maximum tolerated dose was determined to be dose level 4: 150 mg Erlotinib, 250 mg/m2 Cetuximab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Correlated With Best Overall Response.</title>
        <description>To determine the efficacy, as measured by objective tumor response rate (RICIST criteria), of daily oral erlotinib and weekly intravenous cetuximab in patients with advanced NSCLC. Best overall response per patient will be reported below.</description>
        <time_frame>Every two cycles from first dose to last dose of study drugs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib + Cetuximab</title>
            <description>cetuximab: Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
erlotinib: Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Correlated With Best Overall Response.</title>
          <description>To determine the efficacy, as measured by objective tumor response rate (RICIST criteria), of daily oral erlotinib and weekly intravenous cetuximab in patients with advanced NSCLC. Best overall response per patient will be reported below.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete/Partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Outcome</title>
        <description>In the Phase II portion of the study, patients will be followed for both disease free progression by capturing disease progression date and for over all survival by capturing death date.</description>
        <time_frame>Patients will be followed until death</time_frame>
        <population>44 patients were enrolled into the Phase II portion of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II Expansion</title>
            <description>44 Patients at dose level 4 phase II expansion: 150 mg Erlotinib, 250 mg/m2 Cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Outcome</title>
          <description>In the Phase II portion of the study, patients will be followed for both disease free progression by capturing disease progression date and for over all survival by capturing death date.</description>
          <population>44 patients were enrolled into the Phase II portion of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Deceased</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not followed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Withdrew consent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive when study terminated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected day 1 of every cycle for enrolled patients. Total time of collection for all patients: 6 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib + Cetuximab</title>
          <description>cetuximab: Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
erlotinib: Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acneiform rash</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Rash NOS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Rash desquamtion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Data Manager</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>916-734-8381</phone>
      <email>nmahaffey@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

